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Abstract 
Acetaminophen (APAP) overdoses are of major clinical concern. Growing evidence 
underlines a pathogenic contribution of sterile post-injury inflammation in APAP-induced 
acute liver injury (APAP-ALI) and justifies development of anti-inflammatory therapies with 
therapeutic efficacy beyond the therapeutic window of the only current treatment option, N-
acetylcysteine (NAC).The inflammatory mediator high mobility group box 1 (HMGB1) is a 
key regulator of a range of liver injury conditions and is elevated in clinical and preclinical 
APAP-ALI. The anti-HMGB1 antibody (m2G7) is therapeutically beneficial in multiple 
inflammatory conditions and anti-HMGB1 polyclonal antibody treatment improves survival 
in a model of APAP-ALI. Herein, we developed and investigated the therapeutic efficacy of a 
partly humanized anti-HMGB1 monoclonal antibody (h2G7) and identified its mechanism of 
action in preclinical APAP-ALI. The mouse anti-HMGB1 monoclonal antibody (m2G7) was 
partly humanized (h2G7) by merging variable domains of m2G7 with human antibody-Fc 
backbones. Effector function deficient variants of h2G7 were assessed in comparison with 
h2G7 in vitro and in preclinical APAP-ALI. h2G7 retained identical antigen-specificity and 
comparable affinity as m2G7. 2G7 treatments significantly attenuated APAP-induced serum 
elevations of ALT, miR-122 and completely abrogated markers of APAP-induced 
inflammation (TNF, MCP-1 and CXCL-1) with prolonged therapeutic efficacy as compared 
to NAC. Removal of complement and/or Fc receptor binding did not affect h2G7 efficacy. 
Conclusion: This is the first report describing the generation of a partly humanized HMGB1-
neutralizing antibody with validated therapeutic efficacy and importantly, with a prolonged 
therapeutic window as compared to NAC in APAP-ALI. The therapeutic effect was mediated 
via HMGB1 neutralization and attenuation of post-injury inflammation. These results 
represent important progress towards clinical implementation of HMGB1-specific therapy as 
a means to treat APAP-ALI and other inflammatory conditions.   
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Introduction 
Drug-induced liver injury (DILI) is the leading cause of acute liver injury (ALI), which is 
both a clinical concern and results in drug attrition, issuing of black box warnings and drug 
withdrawal from the market (1). Acetaminophen (APAP) is an analgesic and antipyretic and 
is generally safe when taken at therapeutic dose, however intentional or unintentional 
overdoses can lead to APAP-induced acute liver injury (APAP-ALI) and represent around 
50% of all cases of acute liver failure (ALF) (2, 3). Clinical APAP intoxication is 
counteracted by peroral or intravenous administration of N-acetylcysteine (NAC), which has a 
narrow window for therapeutic intervention. Untreated, APAP overdoses can lead to 
fulminant liver failure and the clinical outcome ranges from full recovery, a need of liver 
transplantation or even death. The post APAP associated inflammation (especially innate 
immune activation), resulting from a substantial hepatocellular necrosis, is negatively 
associated with poor clinical outcome (i.e. need for liver transplant or death). For late 
presenting patients, in whom inflammatory responses are fulminant (4), there are no effective 
treatment options for severe cases of ALF beside liver transplantation. Due to the shortage of 
potential liver donors and cost of liver transplantations, there is an urgent need for 
development of alternative therapeutic strategies with broader therapeutic time windows than 
NAC, including immunomodulatory drugs, in preventing APAP-ALI progression. 
High mobility group box 1 (HMGB1) was discovered 16 years ago as an endogenous 
inflammatory mediator and now serves as a prototype for the class of pro-inflammatory 
mediators denoted Alarmins. Alarmins are released passively during cell death or from 
stressed cells. During infectious and sterile inflammatory conditions, HMGB1 is also actively 
released by immune cells, enhancing and perpetuating inflammation and thus contribute to the 
pathogenesis of a great number of inflammatory diseases. The diverse inflammatory functions 
of HMGB1 are mediated via multiple, different reciprocal receptors. Global structural 
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changes associated with cysteine redox modifications of HMGB1 control its receptor usage 
and thereby its bioactivities. HMGB1 induces cell migration in its fully reduced, all-thiol form 
when interacting with CXCL-12 and CXCR-4 (5) whereas cytokine production is induced by 
the disulfide form interacting with the MD-2/TLR4 receptor complex (6, 7). Furthermore, 
HMGB1 has also been demonstrated to signal via RAGE, TLR2, TLR9, CD24/Siglec, and 
TIM-3 (8), with undetermined requirements for possible post-translational modifications. 
Additionally, the active secretion of HMGB1 is regulated by acetylation of HMGB1 (9), an 
HMGB1-specific modification that negatively correlates with APAP-ALI patient outcome 
(10).  
HMGB1 plays a critical role in a wide array of liver disease conditions, including liver 
ischemia-reperfusion (I/R) injury, alcoholic liver disease (ALD), cholestasis and DILI. In 
liver I/R injury, necrotic cell death is prominent and HMGB1 is released (11). The pathogenic 
contribution of HMGB1 in hepatic I/R has recently been shown through blockade of the 
interaction between HMGB1 and MD-2 (7). Acetylated HMGB1 has been recorded in ALD 
patients and ethanol-fed mice, demonstrating an inflammatory component and active HMGB1 
release in ALD. Furthermore, conditional hepatocyte ablation of Hmgb1 is protective in a 
mouse model of ethanol-induced liver injury (12). Similar HMGB1 isoforms have been 
recorded in obstructive cholestasis patients (13), supporting an active release and 
inflammatory role of HMGB1 in this disease as well. HMGB1 is required for the post-APAP 
injury inflammation and has been shown to be pivotal in the progression of APAP-ALI and 
hepatocyte-specific HMGB1 deficiency improves survival (14). In a clinical setting, HMGB1 
serves as a promising sensitive and specific biomarker of APAP-ALI, outperforming alanine 
aminotransferase (ALT) as marker of progression and as indicator of outcome (2, 10). The 
initial APAP-induced hepatocyte necrosis results in an initial release of all-thiol HMGB1. 
This leads to recruitment and activation of immune cells, which propagate the inflammatory 
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response, resulting in increased hepatocyte death and exacerbation of injury (14). HMGB1-
specific antibody treatments have consolidated the pathogenic contribution of HMGB1 in 
APAP-ALI, demonstrating increased survival (15). 
Therapies targeting either the release of HMGB1, interfering with HMGB1-receptor 
signaling or directly antagonizing HMGB1 (i.e. box A therapy) ameliorate disease severity 
and promote survival in a wide spectrum of experimental disease models (16). These 
therapies are however unspecific in the sense that they may affect other ligand-receptor 
interactions or signaling pathways utilized by other molecules than HMGB1. They may thus 
not be suitable for clinical use. Importantly, targeting HMGB1 with the use of antibodies 
specifically affects extracellular HMGB1 bioactivities but will not interfere with its 
intracellular functions. Successful HMGB1-specific polyclonal antibody therapy was first 
described in an acute inflammatory model of sepsis (17) and later in a chronic setting of 
experimental arthritis models (18). Polyclonal and monoclonal antibody (mAb)-based 
therapies are powerful tools in preclinical research. However, long-term clinical success in 
humans with such antibodies is hampered by the inherent immunogenicity of xenogeneic 
antibodies that may cause safety issues and a negative impact on the clinical efficacy (19). 
The development of humanized antibodies has significantly reduced the restricting 
xenogeneic immune responses. Chimeric antibodies, humanized antibodies with the antigen-
binding region kept xenogenic, targeting self-antigens are presently used successfully to treat 
cancer (anti-CD20/rituximab), graft-versus-host disease (anti-CD25/basiliximab) and various 
autoimmune diseases (anti-TNF/infliximab). The heterogeneity of diseases or disorders with 
an inflammatory component emphasizes a continuous search for treatment refinement and 
creation of future therapies that specifically targets novel pathogenic molecules.  
To enable development of HMGB1-targeted therapy for clinical use, we set out to 
engineer a chimeric anti-HMGB1 mAb (h2G7) by preserving the variable regions of an 
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extensively studied and effective mouse mAb (m2G7) with recorded beneficial anti-
inflammatory effects in multiple preclinical models (Supplementary Table 1). To verify well-
maintained beneficial therapeutic effects we utilized a highly HMGB1-dependent 
experimental model of APAP-ALI, which established that h2G7 provided equal therapeutic 
benefit as its murine analog. By modification of the CH2 domain we could generate a variant 
of h2G7 unable to activate the classical complement pathway (K322A mutant), and an h2G7 
variant incapable of binding Fc-receptors (endoS-treated h2G7). By comparing the therapeutic 
in vivo efficacy of these three mAb variants we conclude that h2G7 treatment alleviated 
APAP-ALI via HMGB1 neutralization and has a prolonged therapeutic window as compared 
to NAC treatment.  
Materials and methods 
A detailed description of experiments is described in supplementary methods. 
A chimeric anti-HMGB1 antibody (h2G7) with human IgG1 isotype was generated as 
described previously (20, 21). Briefly, DNA encoding the 2G7 mouse variable 
immunoglobulin domains was PCR amplified (Supplementary Table 2) and subcloned into 
plasmids encoding human constant domains. Antibody specificity was tested by coating plates 
with HMGB1, box A or box B followed by titration with increasing concentrations of mAbs. 
Affinities were analyzed by SPR. Briefly, mAbs were immobilized on a CM5-dextran chip 
and recombinant HMGB1 was injected at various concentrations (0nM, 55nM, 110nM, 
220nM and 880nM). Determination of dissociation constants was performed using Langmuir-
binding.  
Male C57BL/6J or CD-1 mice (Charles River) were fasted (15-16h) before 
intraperitoneal (IP) injection of APAP (530 or 300mg/kg when indicated)(Supplementary Fig. 
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1). At 2h post-APAP (or 6h when indicated), 300µg of anti-HMGB1 antibodies, box A, E2 
(irrelevant isotype control) or 500mg/kg NAC were injected IP. At 10h post-APAP (or 24h 
when indicated), liver injury was determined by histology, serum ALT and expression of 
miR-122. Inflammatory mediators were analyzed by cytometric bead array (CBA)(BD 
Bioscience).  
Effector function deficient variants of h2G7, incapable of binding complement or Fc 
receptors were generated by site-directed mutagenesis (K322A, Supplementary Table 2) or by 
endoglycosidase-S (endoS) treatment. Inability to activate complement was validated by a 
decrease in C1q deposition from normal human serum (NHS). Antibody deglycosylation was 
validated by a characteristic mass-shift (SDS-PAGE analysis) and LCA binding. Briefly, 
antibodies were coated onto plates followed by addition of biotinylated-LCA and 
subsequently visualized with Streptavidin-HRP and TMB. FcγR-binding was performed by 
binding of antibodies to human CD64 coated plates or to live THP-1 cells. For binding to 
THP-1 cells, h2G7 variant antibodies were incubated with cells followed by detection with a 
FITC-conjugated F(ab’)2 anti-human antibody. 
Statistical analysis for in vivo studies was performed with Kruskal-Wallis (Dunns post-
test) and for in vitro data, one-way ANOVA was performed where indicated. All statistical 
analysis was performed using Graphpad Prism. 
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Results 
Characterization of chimeric 2G7 mAb bioactivities 
We merged the variable domains of 2G7, obtained from mouse (m2G7) hybridoma cells, 
with plasmids encoding the human IgGγ1 isotype and IgGκ backbone in order to generate a 
chimeric anti-HMGB1 antibody (h2G7) (Fig. 1A). The specific parent anti-HMGB1 antibody 
(m2G7), that does not recognize HMGB2, binds to the amino acids 53-63 within the box A 
domain of rodent and human HMGB1 (22). Since antibody specificity may be influenced by a 
change of IgG isotype (23), we examined the antigen-specificity of h2G7 compared to m2G7. 
In similarity to m2G7, h2G7 displayed dose-dependent binding to full-length HMGB1 and the 
box A domain but not to the box B domain (Fig. 1B). By utilizing surface plasmon resonance 
(SPR) we defined the antibody binding affinities for m2G7 (Kd 170nM) and h2G7 (Kd 
130nM) (Fig. 1C). This suggests that h2G7 had a slightly higher affinity towards HMGB1 as 
compared to its murine counterpart, although the recorded affinities were within the same 
order of magnitude. The human irrelevant IgG1 isotype control (E2) (20) did not bind to 
HMGB1, or the box A or box B domains (Fig. 1B and C). Distinct functional HMGB1 
cysteine redox isoforms are present during different phases of APAP-induced inflammation 
(6, 15) and it was previously unknown whether 2G7 selectively binds to any of these redox 
isoforms. We therefore evaluated the binding capacity of m2G7 (Fig. 1D) and h2G7 (Fig. 1E) 
to all-thiol, disulfide and sulphonyl HMGB1. Both m2G7 and h2G7 displayed equal binding 
to all three isoforms tested indicating that 2G7 has the capacity to antagonize HMGB1 during 
separate stages of inflammation.  
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Equivalent therapeutic effects of h2G7 and m2G7 
The therapeutic in vivo effects of h2G7 were evaluated in an experimental model of 
APAP-induced ALI (Supplementary Fig. 1). The pathogenic importance of HMGB1 in this 
model has previously been established by several reports (2, 7, 15, 24, 25). Non-APAP 
challenged C57BL/6 mice were treated with PBS (vehicle), h2G7, m2G7 or the control E2 
antibody. None of the treatments significantly affected hepatic glutathione (GSH) levels as 
compared to the PBS control, indicating that the treatments alone did not affect the hepatic 
APAP-scavenging ability or APAP-bioconversion (Fig. 2A). No difference was recorded 
between the treatment groups in non-APAP challenged mice with respect to serum ALT or 
microRNA-122 (miR-122), a sensitive biomarker for hepatocyte damage (Supplementary Fig. 
2A and B). These results indicate that antibody treatments were neither hepatotoxic nor did 
they alter baseline levels of systemic liver injury markers.  
Mice challenged with APAP for 10h demonstrated characteristic hepatic 
pathophysiological changes as compared to normal mice (Fig 2D and Supplementary Fig. 3). 
Hepatic tissue expression of HMGB1 was lost in central necrotic areas but upregulated in the 
periportal areas (Supplementary Fig. 3). In mice challenged with APAP for 10h, the hepatic 
GSH concentrations dropped from 32.4±6.2 to 5.1±1.9 nmols/mg±SD (Fig 2A). A similar 
decrease in hepatic GSH was seen in all mice treated 2h post-APAP with PBS, E2, m2G7 and 
h2G7 indicating comparable APAP metabolism between the treatment groups (Fig. 2A). In 
concordance with previous studies based on antibodies targeting HMGB1 in APAP-
challenged mice (7, 15), 2G7 treatments mediated a significant reduction in serum ALT and 
miR-122 levels compared to the E2 control group (Fig. 2B and C). No significant difference 
was observed between the m2G7 and h2G7 treatment groups indicating equivalent hepato-
protective properties (Fig. 2B and C). Confirmatory histological results were recorded and 
revealed reduced tissue destruction and alleviated inflammation in the h2G7 treated mice (Fig. 
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2D and E). A clear trend in hepato-protection as analyzed by histology was also seen with 
m2G7 treatment, although this difference was not statistically significant (Fig. 2E). 
Quantification of Ki-67 stained liver sections revealed that both m2G7 and h2G7 treatment 
had significantly less proliferating hepatocytes as compared to livers of E2-treated mice 
(Supplementary Fig. 4), suggesting a decrease in liver regeneration at 10h post-APAP. 
However, this may be explained by the decrease in liver injury seen in m2G7 and h2G7 
treated mice (Figure 2B-E).  
Inflammatory mediators are upregulated as a result of the initial toxic hepatocellular 
injury induced by APAP exposure (26, 27). Both PBS- and E2-treated mice demonstrated a 
significant increase in serum levels of MCP-1, CXCL-1 and TNF in APAP-exposed mice 
compared to non-APAP challenged animals (Fig. 2F). Anti-HMGB1 treatments significantly 
reduced APAP-induced serum levels of MCP-1 and completely abolished the serum levels of 
CXCL-1 and TNF as compared to the E2 treatment group. We also measured serum levels of 
IL-1β and IFN-γ, since both have been reported upregulated after APAP administration (27). 
However, these cytokines were undetectable in our experiments (data not shown).  
Furthermore, studies were conducted to evaluate lowest effective therapeutic dose by 
administering one and two orders of magnitude less of h2G7 antibody (i.e. 300, 30 or 
3µg/mouse). A dose-dependent decrease in serum ALT and miR-122 (Fig. 3A and B) was 
observed. Interestingly, the lowest dose of h2G7 (3µg) did not significantly decrease serum 
levels of ALT or miR-122, but were still able to significantly block APAP-induced 
inflammation (Fig. 3C). The release of the hepatocyte biomarkers is a combined consequence 
of direct APAP-mediated toxicity and of the subsequent inflammation. 
In order to explore whether the recorded hepato-protection of 2G7 treatment was an 
effect observed exclusively in inbred mice we also investigated the therapeutic effect of 
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m2G7 treatment in outbred CD-1 mouse strain. In agreement with the results observed in 
C57BL/6 mice, m2G7-treated CD-1 animals expressed significantly reduced serum levels of 
ALT as compared to PBS-treated animals (Fig. 3D). HMGB1-induced inflammatory effects 
are known to be antagonized by the truncated box A domain of the HMGB1 molecule, by 
means that are not fully resolved. These therapeutic results have previously been 
demonstrated in multiple experimental disease models (18, 28, 29), but never before studied 
in APAP-ALI. A single IP injection of box A showed similar hepato-protective effects as the 
m2G7 treatment (Fig. 3D), confirming that other strategies for extracellular HMGB1 blockade 
are also beneficial in APAP-ALI. Injection of box A or m2G7, in non-APAP challenged CD-1 
mice, did not alter the levels of hepatic GSH or serum levels of ALT (Supplementary Fig. 4A 
and B). In line with these observations, a uniform decrease of hepatic GSH was seen in all 
APAP challenged CD-1 mice regardless of treatment (Supplementary Fig. 5A). 
Specific anti-HMGB1 therapy has a delayed therapeutic window as compared to NAC  
Post-injury inflammation is highly deleterious in APAP-ALI patients and is especially evident 
in late-presenting patients were NAC treatment fails to confer hepato-protection. We therefore 
wanted to investigate whether anti-HMGB1 treatment provided an extended window of 
therapeutic intervention. APAP challenged mice (300mg/kg) were treated with either NAC, 
E2 or h2G7 at 2h post-APAP or 6h post- APAP and monitored for 24h. In line with previous 
reports, NAC treatment at 2h post-APAP completely abrogated the increase in serum ALT 
(Fig 4A). However, NAC failed to confer hepatoprotection at 6h post-APAP whereas h2G7 
treatment was hepatoprotective at both 2h and 6h post-APAP as measured by serum ALT 
levels (Fig. 4A and B). The reality in the clinic is that all APAP-ALI patients (depending on 
serum APAP concentration??) receive NAC-treatment and we thus, in addition, investigated 
the effect of NAC-h2G7 combination treatment. We could not record any beneficial effects of 
the combination treatments at any time point (Fig. 4A and B), supporting that h2G7 treatment 
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rather targets the post-injury inflammation than the initial metabolic injury that is 
counteracted by NAC treatment.  
Generation of effector function-deficient h2G7 variants 
Immunomodulatory effects of antibody therapies can be mediated via several different 
mechanisms. Antibodies may block the function of an antigen by binding and neutralizing its 
target, by activating the classical complement pathway through interaction with C1q or by the 
engagement of Fcγ receptors (FcγR) and thus inducing cell-mediated effects. In order to 
outline the therapeutic importance of Fc-mediated effector functions of h2G7 antibody in 
APAP-ALI, we generated effector function-deficient variants by modifying its CH2 domain 
either by site-directed-mutagenesis or by endoS treatment, which removes N-linked 
glycosylation on Fc part of antibodies (30-32). Importantly, none of the Fc-modified variants 
of h2G7 affected the binding to HMGB1 (data not shown). A lysine-to-alanine mutant variant 
of h2G7 was generated (K322A), and in contrast to non-modified h2G7, The K322A variant 
completely abolished binding to human C1q in vitro when coated directly (Fig. 5A) or when 
bound to plates coated with HMGB1 (Fig. 5B). In similarity to the K322A mutant, endoS-
treated h2G7 did not bind to C1q (data not shown).  
Hydrolysis of the N-linked glycan at position N297 by endoS treatment was verified by a 
characteristic mass-shift (Fig. 6A) and by a reduced binding to Lens culinaris agglutinin 
(LCA) (Fig. 6B and Supplementary Fig. 6A), which specifically binds to N-linked glycans. 
To verify that deglycosylation reduced FcR binding we evaluated this binding in vitro. 
Human IgG1 has the capacity to bind and activate all members of the FcγR family and, as 
predicted, deglycosylation of h2G7 ablated binding to human recombinant FcγRI/CD64 (Fig. 
6C and Supplementary Fig. 6B). We further investigated binding of h2G7 to human THP-1 
cells that express both CD64 and FcγRII/CD16. The endoS treatment significantly reduced 
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binding of h2G7 to THP-1 cells (Fig. 6D and Supplementary Fig. 6C). The K322A mutant 
and non-modified h2G7 displayed similar binding to LCA, CD64 and THP-1 cells (data not 
shown).  
Therapeutic properties of effector function-deficient h2G7 
We next studied the therapeutic in vivo efficacy of the effector function-deficient h2G7 
variants in order to elucidate the mechanism by which h2G7 elicits its hepato-protective and 
anti-inflammatory effect. Treatment with the modified variant antibodies (K322A and endoS-
treated h2G7) and h2G7 in APAP-challenged mice showed similar hepato-protective effects, 
as determined by a comparable reduction of serum ALT (Fig. 7A) and miR-122 
(Supplementary Fig. 7B). Equivalent anti-inflammatory effects, as measured by reduced 
levels of TNF (Fig. 7B), CXCL-1 (Fig. 7C) and MCP-1 (Fig. 7D), were also recorded. These 
results collectively establish that the therapeutic effects of h2G7 were mediated via HMGB1 
neutralization rather than via complement activation or Fc receptor-mediated effects. 
Discussion  
APAP is one of the most common over-the-counter drugs and is generally safe at 
recommended therapeutic doses. Nevertheless, APAP intoxication is a clinical problem and 
may result in ALI or even death. During clinical APAP overdose, a worse prognosis is 
correlated with activation of post injury inflammation and systemic inflammatory response 
syndrome (SIRS) (2, 4, 27, 33). Given the inadequacy of current therapy (i.e. NAC), 
especially in late-presenting patients, there is a need for development of novel therapies 
targeting the post-injury inflammation. Specific immune-modulatory therapies are as of yet 
not available as treatment options for APAP-ALI although such therapeutic strategies would 
potentially prolong the therapeutic window. Indeed, our data strongly supports that anti- 
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HMGB1 therapy significantly prolongs the therapeutic window of experimental APAP-ALI 
(Fig. 3) and would likely be invaluable in treatment of late-presenting patients or in patients 
that do not respond satisfactory to NAC. HMGB1 has been shown to be a pivotal regulator 
and biomarker of injury as a result of APAP overdose (2, 10). Therapeutic neutralization of 
HMGB1 has the potential to improve outcome of several human diseases but no published 
clinical trials using HMGB1-specific inhibitors have so far been conducted. A paucity of 
HMGB1 antagonists suitable for the clinic has until now been the major restricting element 
for further progress. Accordingly, the main purpose of this study was to engineer a chimeric 
HMGB1-specific mAb with the potential to be evaluated in future clinical trials, by 
investigating its therapeutic efficacy in a previously shown HMGB1-dependent experimental 
model of APAP-ALI. We believe that the outcome of our study, the partly humanized h2G7, 
represents a promising candidate for further clinical exploration. 
Conserved proteins are poor immunogens and raising protective therapeutic monoclonal 
antibodies (mAbs) that target such proteins is a challenging enterprise (34). Hence, generating 
therapeutically efficient mAbs specific for HMGB1 (99% sequence conservation in 
mammalians) has proven no exception to this experience. It took several years after the 
original polyclonal anti-HMGB1 antibody treatment study (17) until an anti-HMGB1 mAb 
(m2G7) was demonstrated to confer experimental disease protection (22, 35). Although a few 
additional mouse mAbs targeting HMGB1 have mediated successful results in preclinical 
disease models (36, 37), none has demonstrated comparable universal therapeutic efficacy as 
the 2G7 mAb that ameliorates diverse inflammatory disease models (Supplementary Table 1).  
The generated chimeric 2G7 antibody with itsreplacement of the constant m2G7 frameworks 
with human sequences may possibly meet the drug development requirements for an HMGB-
specific antibody therapy that would be suitable for clinical trials. Humanization processes 
may alter both specificity and affinity of an antibody (23) and for that reason we investigated 
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whether a change in the constant immunoglobulin framework modified the in vitro properties 
of 2G7. Our results indicate that h2G7 did not interact with anti-mouse IgG antibodies, 
implicating that removal of the murine constant frameworks significantly reduced 
immunogenicity (data not shown) but with preserved antigen-specificity and affinity (Fig. 1B 
and C).  
The therapeutic efficacy of m2G7 in preventing HMGB1-induced sterile inflammation 
has emphasized the clinical potential of 2G7 in several disorders (Supplementary table 2) and 
especially in hepatic disorders (7, 35). HMGB1 levels are increased in clinical and 
experimental APAP-ALI and surpass ALT as a predictor of clinical outcome after APAP 
intoxication (2, 10). The central functional role of HMGB1 in APAP-ALI pathogenesis is 
highlighted by the fact that hepatocyte specific abrogation of Hmgb1 and anti-HMGB1 
treatment is highly protective in experimental model APAP-ALI (7, 14). In addition, 
extensive post-injury inflammation negatively correlates with patient outcome (i.e. need for 
liver transplant or death). Our results based on therapeutic interventions with h2G7 or m2G7 
are in full agreement with this concept and confirm retained functionality of the novel h2G7 
antibody. Furthermore, therapeutic intervention with h2G7 is superior to NAC treatment at 
late time points of experimental APAP-ALI, possibly providing a novel treatment specifically 
targeting post-injury inflammation with a prolonged therapeutic window of opportunity at 
which NAC treatment fails to confer hepato-protection. 
Recent structural HMGB1 studies emphasize that the redox states of its three conserved 
cysteine residues regulate the receptor-binding ability and subsequent biological functions. 
Fully reduced HMGB1 (all-thiol) acts a chemotactic factor, partially oxidized HMGB1 
(disulfide) induces cytokines via the TLR4/MD-2, while the fully oxidized HMGB1 
(sulfonyl) exerts no demonstrable inflammatory activity (6, 38, 39). All three isoforms are 
systemically present in APAP challenged mice although at different stages of the post-injury 
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inflammation (6). HMGB1 isoforms (various redox and acetylated isoforms) are readily 
detected by 2G7 in immunoblot analysis (data not shown) or by direct-ELISA (Fig 1D and E), 
but we cannot further comment on conceivable binding preferences of the antibodies to any of 
the HMGB1 isoforms in vivo. It has previously been demonstrated that m2G7 inhibits both 
HMGB1-induced cytokine production (39) as well as HMGB1-induced cell migration in vitro 
(personal communication with prof. Marco E. Bianchi). Our in vivo-based studies further 
support that h2G7 and m2G7 inhibits HMGB1-driven cytokine and chemokine release in 
experimental APAP-ALI equally well (Fig. 2F). Likewise, several in vivo models of sterile 
inflammation have demonstrated that m2G7 suppresses both HMGB1-induced migration and 
cytokine production (Supplementary Table 1). This collectively suggests that 2G7 hampers 
the effect of both known inflammatory isoforms of HMGB1. 
The hepato-protective effects and elimination of inflammatory mediators in response to 
2G7 treatment, underline the pathogenic contribution of inflammation in APAP-ALI and that 
APAP-induced inflammation is highly HMGB1-dependent. A single injection of 3µg of h2G7 
as well as the hepato-protective dose of 300µg completely eliminated the studied circulating 
inflammatory mediators (Fig. 3). Yang et al. demonstrated that treatment with low-dose 
m2G7 (5µg) per mouse at 2h and a repeated dose at 7h post-APAP was both hepato-protective 
and anti-inflammatory at 24h post-APAP (7). The higher dose required in our study for 
hepato-protection could possibly be explained by experimental kinetic differences regarding 
the post-injury inflammatory response or that a single low-dose injection of h2G7 is not 
sufficient to confer hepato-protection. Nevertheless, the functional similarities of h2G7 and 
m2G7 in the current study suggest that h2G7 may exert life-saving effects in APAP-induced 
ALI in a clinical setting. 
None of the previous preclinical studies involving m2G7 have addressed the mechanism 
of action of the m2G7 parental antibody. The present generation of a novel chimeric 2G7 
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antibody (h2G7) allowed us to, in a controlled manner, modify its effector functions and thus 
study its mechanism of action. In concurrence with previously published data (40), a K322A 
substitution of h2G7 completely suppressed C1q binding without affecting binding to FcγRs. 
The aglycosylated h2G7 was incapable of binding neither C1q nor FcγRs. Since 
deglycosylation of antibodies may affect binding to C1q it is important to recognize both 
isotype- and species-specific differences especially when conducting studies comparing 
therapeutic antibodies (31, 32, 41). The binding of aglycosylated mouse IgG2b to C1q is 
negligible and it is therefore likely that endoS-treated m2G7 would have the same effect (42). 
Our in vivo data collectively suggest that h2G7 acts through antigen neutralization rather than 
complement activation or FcγR engagement, since neither the K322A mutant nor endoS-
treated h2G7 displayed altered therapeutic activity as compared to non-modified h2G7. The in 
vivo neutralizing effects of 2G7 could possibly be explained by a direct steric blocking of 
HMGB1-receptor interaction. As shown for other therapeutic antibodies, it is conceivable that 
a competition for receptor binding sites is sufficient for the observed HMGB1 neutralization 
by h2G7 or that allosteric mechanisms induce or suppress conformational changes thus 
altering the function of HMGB1 (43). Further in-depth studies are required to define whether 
h2G7 has a preference for certain HMGB1 isoforms and to elucidate the detailed mechanisms 
for h2G7-mediated neutralization.  
To summarize, we here report the creation of a partly humanized, chimeric mAb targeting 
HMGB1 with preserved functionality compared to the parental mouse anti-HMGB1 mAb. We 
conclude that HMGB1 neutralization was the observed mechanism of action in experimental 
APAP-ALI. The h2G7 antibody would likely provide significant advantages in a clinical 
setting due to reduced xenogeneic immune responses and improved pharmacokinetics as 
compared to mouse anti-HMGB1 mAbs, especially in late-presenting patients and in patients 
Page 18 of 62
Hepatology
Hepatology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
19 
 
with a need for repeated treatment. These results provide distinct progress in the endeavor to 
bring an HMGB1-specific antagonist to further clinical development. 
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Figure legends  
Figure 1. 
Chimeric anti-HMGB1 antibody has retained specificity and affinity as its murine analog. (A) 
Constant and variable domain comparison of the parental mAb m2G7 and the chimeric h2G7 
antibody denoted with known key residues regulating antibody effector functions. (B) 
Antigen specificity was tested by direct-ELISA. HMGB1 (left), box A (middle) or box B 
(right) was coated on plates and incubated with antibodies at increasing concentration. h2G7 
(green) and m2G7 (red) displayed similar antigen specificity by binding to both HMGB1 and 
the box A domain but not to box B. The control human IgG1 antibody E2 (black) did not 
display binding to any of the proteins. (C) SPR analysis was performed to define binding 
affinities to HMGB1. Antibodies were immobilized on a CM5-dextran chip and HMGB1 was 
injected at various concentrations (55, 100, 220, 440 or 880nM). h2G7 displayed slightly 
higher affinity (left, Kd = 130nM) towards HMGB1 as compared to m2G7 (middle, Kd = 
170nM). No signal was detected from the E2 channel (right). (D-E) Indicated redox isoforms 
of HMGB1 were coated and (D) m2G7 or (E) h2G7 were added at increasing concentrations 
and detected with anti-mouse IgG or anti-human IgG, respectively.  
Figure 2. 
Similar therapeutic efficacy of h2G7 and m2G7 following APAP-ALI. Fasted C57BL/6 mice 
were subjected to 530mg/kg of APAP. PBS, 300µg m2G7, h2G7 or IgG1 control antibody 
(E2) was administered at 2h post-APAP (n=6). At 10h post-APAP, (A) Hepatic GSH, (B) 
serum ALT (C) serum miR-122 expression, (D) representative histological sections (H&E 
stainings) and (E) histological score were analyzed to evaluate hepatic injury. Levels of the 
inflammatory mediators (F) TNF, CXCL-1 and MCP-1 in serum were quantified. If 
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undetectable, values were substituted with the lowest limit of detection (50pg/mL). Data is 
presented as means±SEM. * = P < 0.05 and ** = P < 0.01 by Kruskal-Wallis with Dunns 
post-test.    
Figure 3. 
Dose-dependent hepato-protection and completely abolished inflammation with anti-HMGB1 
therapy. (A-C) APAP-challenged C57BL/6 mice (530mg/kg) were treated (2h post-APAP) 
with h2G7 (3, 30 and 300µg/mouse) or with 300µg E2 ctrl antibody (n=6). Serum levels of 
(A) ALT and (B) miR-122 indicate a dose dependent hepato-protection with h2G7 as 
treatment and a complete abrogation of (C) inflammatory mediators, independent of 
therapeutic dose. (D) Serum ALT levels in APAP-challenged CD-1 mice (530mg/kg) treated 
(2h post-APAP) with PBS, 300µg m2G7 or 300µg box A for 10h (n = 7). If undetectable, 
values were substituted with the lowest limit of detection (50pg/mL). Data is presented as 
mean±SEM. * = P < 0.05, ** = P < 0.01, and *** = P < 0.001 by Kruskal-Wallis with Dunns 
post-test.  
Figure 4. 
Targeting post-injury inflammation with h2G7 prolongs the therapeutic window of 
opportunity compared to NAC treatment. APAP-challenged C57BL/6 mice (300mg/kg) were 
treated (A) 2h or (B) 6h post-APAP with h2G7 (300µg/mouse), 300µg E2 ctrl antibody 
(300µg/mouse) or NAC (/mouse) alone or in combination (n=10) and sacrificed at 24h post-
APAP. Hepato-protection was recorded as a decrease in serum ALT levels. Data is presented 
as mean±SEM. * = P < 0.05, ** = P < 0.01, and *** = P < 0.001 by Kruskal-Wallis with 
Dunn’s post-test.  
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Figure 5. 
Abrogated binding to complement C1q in vitro by a K322A mutation. Plates were coated with 
indicated antibodies directly or with HMGB1. (A) Deposition of C1q from normal human 
sera (NHS) on plates coated with K322A or h2G7. Human serum albumin (HSA) or 
aggregated human IgG (Agg.IgG) were used as negative and positive controls, respectively. 
(B) K322A did not bind to C1q when complexed with HMGB1. In experiments with HMGB1 
coating, data were normalized towards the h2G7 signal at 1% NHS which was set as 100% 
C1q deposition. Results are represented as means±SEM from three independent experiments. 
Figure 6. 
Aglycosylated h2G7 display reduced binding to Fc receptors in vitro. Deglycosylation of 
h2G7 was performed by endoS treatment and was analyzed by (A) reducing SDS-PAGE. A 
small decrease in mass indicated deglycosylation of the IgGγ chain. (B) Lens culinaris 
agglutinin (LCA) displayed significantly reduced binding to plates coated with endoS-treated 
h2G7 as compared to non-treated h2G7. (C) EndoS treatment of h2G7 significantly reduced 
human recombinant CD64. (D) Binding to live THP-1 cells incubated with PBS, h2G7 or 
endoS-treated h2G7. Results are represented as means±SEM from three independent 
experiments. *** = P < 0.001 by one-way ANOVA with Bonferroni post-test.  
Figure 7. 
Effector-function deficient h2G7 variants demonstrate analogous therapeutic effects as h2G7. 
APAP-exposed C57BL/6 mice (530mg/kg) were treated with 300µg E2, K322A, endoS-
treated h2G7 or h2G7 at 2h post-APAP (n = 6). (A) K322A, endoS-treated h2G7 and h2G7 
demonstrate equivalent hepato-protective effects as measured by serum ALT. No significant 
difference was noted between the h2G7 treatment groups (gray bars) with respect to anti-
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inflammatory activity as measured by a decrease in (B) TNF, (C) CXCL-1 or (D) MCP-1. 
Undetectable levels were substituted with the value for lowest limit of detection (50pg/mL). 
Data is presented as means±SEM. ** = P < 0.01, and *** = P < 0.001 by Kruskal-Wallis with 
Dunn’s post-test. 
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Supplementary data to:  
A novel HMGB1 neutralizing chimeric antibody attenuates DILI and post-injury 
inflammation 
Peter Lundbäck1, Jonathan D. Lea2, Agnieszka Sowinska1, Lars Ottosson3, Camilla 
Melin Fürst4, Johanna Steen1, Cecilia Aulin1, Joanna I. Clarke2, Anja Kipar2, Lena 
Klevenvall3, Huan Yang5, Karin Palmblad3, B. Kevin Park2, Kevin J. Tracey5, Anna 
M. Blom4, Ulf Andersson3, Daniel J. Antoine2,#, and Helena Erlandsson Harris1,# 
 
Supplementary methods 
Cloning and protein purification 
HMGB1, boxA and boxB cloning and production 
All PCR reactions were performed by using Accuprime pfx (Life-technologies, 
Carlsbad, CA) according to manufacturer’s instructions unless otherwise stated. 
HMGB1 cDNA was cloned into a pet28c vector (Novagen) in order to generate 
c-terminal 6xHIS-tagged proteins. Primers (Eurofins DNA) used used to amplify 
cDNA fragments of HMGB1 are stated in SI Table2. Restrictions enzymes used for 
linearization of vector and cleavage of PCR fragment were NcoI and XhoI 
(Fermentas). Linearized vectors were treated with shrimp alkaline phosphatase before 
insertion of cleaved PCR fragments and ligation with T4 DNA ligase (Fermentas). 
Newly generated plasmids were transformed into Oneshot DH5α competent bacteria 
(Life Technologies) by a 30sec, 42°C heat pulse. Kanamycin was used as antibiotic 
for plasmid selection. For recombinant protein production, plasmids were transformed 
into BL-21DE3 bacteria (Life-technologies) and expression was induced by addition 
of 1mM IPTG for 16h at room temperature. Bacteria were lyzed in buffer A 
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(imidazole 20mM and 500mM NaCl) by 4x30sec sonication on ice. Lysate was 
cleared from debris by centrifugation at 15,000g. Recombinant protein purifications 
were performed on an ÄKTA Explorer 10 system according to manufacturer’s 
instructions and all buffers used were filtered (0.2µm) and degased before use. 
Briefly, a HIS-TRAP FF column was equilibrated with 5 column volumes of buffer A 
before injection of bacterial lysate. The column was washed with increasing 
concentrations of imidazole (up to 80mM) and protein was eluted with 200mM 
imidazole and 500mM NaCl. High purity fractions were pooled and the final product 
was >95% pure. Protein preparations were extensively dialyzed against PBS. 
Generation of a chimeric anti-HMGB1 antibody 
Cloning was performed as previously described [1, 2]. RNA from hybridoma cells 
producing monoclonal m2G7 antibodies was isolated by RNeasy columns (Qiagen). 
Superscript (Life-Technologies) was used to synthesize cDNA. IgGγ and IgGκ 
variable regions were amplified separately starting from 4µL of cDNA as template 
with primers stated in SI. Table2. Each round of PCR (50 cycles) was 94°C for 30sec, 
58°C for 30sec, and 72°C for 45sec. PCR products were purified using QIAquick 
PCR purification kit (Qiagen) and digested with restriction enzymes stated in SI. 
Table2 (New England Biolabs). Digested products were ligated using the quick ligase 
kit (New England Biolabs) into expression vectors containing the human IgGγ and 
IgGκ constant regions. Constructs were transformed into DH5α (Invitrogen) and 
propagated plasmids were isolated with NucleoSpin plasmid DNA isolation kit 
(Macherey-Nagel). IgGγ and IgGκ plasmids were sequenced (Eurofins DNA) to 
confirm identity and correct reading frames with the original m2G7 variable region. 
The irrelevant IgG1 isotype control antibody E2 has specificity towards tetanus toxin 
and was originally published as 1362SF-E02 [2]. 
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Recombinant antibodies were produced by transient transfection of FreeStyle 
HEK-293F cells (Gibco, Life Technologies). Cells were cultured at 37°C with 8% 
CO2 in FreeStyle 293 Expression medium (Gibco, Life Technologies) to a density of 
0.6-0.7x106 cells/mL. The cells were then transfected with 0.5µg of vector DNA for 
each antibody chain (heavy and light) per mL of cell culture, using the PEI-Max 
transfection reagent (Polysciences) dissolved in OPTI-PRO SFM medium (Gibco, 
Life Technologies). Supernatants were collected at 9-10 days post-transfection and 
antibodies were purified on HiTrap Protein G HP columns (GE Healthcare) using an 
ÄKTA Explorer 10 system (GE Healthcare). PBS was used as running buffer and the 
antibodies were eluted with 0.1M glycine (pH 2.7) and neutralized with a suitable 
amount of 1M Tris buffer (pH 9.0). Antibodies were extensively purified against PBS 
and concentrations were determined by Nanodrop ND-1000 (Thermo Scientific), and 
the purity (>98%) of the expressed antibodies was determined by SDS-PAGE . 
 
Generation of K322A mutant 
An 18-cycle PCR reaction was performed with h2G7 IgGγ plasmid as template 
with primers stated in SI. Table2. After PCR-cycling, template DNA was digested by 
DpnI digestion for 1h at 37°C. PCR produced plasmids were purified by gel 
extraction and sequenced in order to verify the expected codon change (AAG/GCG).   
Antibody specificity testing 
1µg HMGB1, box A or box B was coated in an ELISA microtiter plate (Nunc 
maxisorp) at room temperature overnight. Plates were blocked in 1% BSA in PBS 
(pH 7.4) for 1h at room temperature. Wash steps were performed with 3x PBS-Tween 
(0.05%). h2G7, m2G7, K322 or E2 was diluted (100, 10, 1 and 0.1 ng/mL) in 
antibody diluent (0.1% BSA, 0.05% Tween-20 in tris-buffered saline, pH 7.4) and 
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incubated at room temperature for 2h. Anti-human or anti-mouse IgG was diluted to 
1:10000 in antibody diluent and incubated for 1h at room temperature. 3,3',5,5'-
tetramethylbenzidine (TMB) substrate was added and stopped after 5min with 2N 
sulphuric acid. Optical density at 450nm was determined (with subtraction of plate 
blank).  
Surface plasmon resonance (SPR) kinetic experiments 
Kinetic experiments were performed on a Biacore 2000 system (GE Healthcare, 
Uppsala, Sweden) according to manufacturer’s instructions unless otherwise stated. 
All buffers and samples were 0.2µM filtered and degased prior to use and the Biacore 
system was primed with running buffer (PBS-T 0.01%). Immobilization; 
Immobilization pH scouting was performed for the h2G7 antibody and the identified 
optimal settings were adapted for all antibodies. Antibodies were diluted in 10mM 
sodium acetate, pH 5.0, and immobilized on a CM5 sensor chip by amine coupling 
using N-hydroxysuccimide (NHS) and N-ethyl-N-(3-dimethylaminopropyl)-
carbodiimide hydrochloride (EDC). Target level for ligand immobilization (RL) was 
calculated and set to 600 in order to achieve a theoretical Rmax of 200. Flow channel 1 
(Fc1) was used as reference surface (blank), Fc2 was immobilized with E2, Fc3 with 
h2G7 and Fc4 with m2G7 antibody. Reactive esters that were not cross-linked were 
blocked with ethanolamine and 50mM NaOH was used as wash buffer after 
immobilization. Kinetic analysis; A two-fold serial dilution of the analyte HMGB1 
was performed (880nM, 440nM, 220nM, 110nM, 55nM and 0nM) in PBS-T. 
Experiments were performed in direct binding mode at a 30µL/min flow rate at 25ºC 
and injection time for HMGB1 (sorted low to high concentration) was 3min followed 
by a dissociation time of 15min before regeneration with two 45sec pulses of 
regeneration buffer (10mM Glycine-HCl pH 2.0, 1M NaCl). Stabilization time after 
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every regeneration buffer injection was set to 2min. Data analysis; Data was 
evaluated using BiaEvaluation. Unnecessary data was subtracted and baselines were 
adjusted to zero. For each HMGB1 concentration injected, the reference surface 
signal from Fc1 was subtracted from the other channels (i.e. Fc2-Fc1, Fc3-Fc1 and 
Fc4-Fc1). The binding curves were also blank-run subtracted by removing the 0nM 
signal for all concentrations. Curve fitting was done by simultaneous Ka/Kd analysis 
(1:1 Langmuir binding) and a Chi2/Rmax < 1% was considered as a good fit.  
Redox isoform specificity 
1µg disulfide HMGB1 (HMGBiotech, Milano, Italy) was coated for 16h at 4ºC in 
microtiter plates in 5mM DTT, PBS or 10mM H2O2 to generate all-thiol, disulfide or 
sulphonyl HMGB1. Plates were blocked with 1% BSA for 1h. Increasing 
concentrations of m2G7 or h2G7 (0.1 – 1000 ng/mL) was added and incubated for 2h 
at room temperature. Bound antibodies were detected with either HRP-coupled anti-
mouse IgG (Sigma-Aldrich, A3854) or anti-human IgG (DAKO Cytomation, 
Glostrup, Denmark, P0214)  
Effector function validations assays 
Deglycosylation of h2G7 was performed using deGlycIT columns (Genovis, Lund, 
Sweden) according to manufacturer’s instructions.  
Gelshift assay; 3.75µg antibody was subjected to SDS-PAGE on tris glycine 4-20% 
gradient gels (BioRad). Gel was stained with Coomassie blue and destained in 10% 
acetic acid and 40% methanol. Deglycosylation effect was verified by a small mass-
shift decrease for IgGγ. 
Lens Culinaris Agglutinin (LCA) binding assay; Half-area microtiter ELISA plates 
(Corning) were coated with antibodies at 37°C for 2h. Between each step after 
coating, plates were thoroughly washed 5x with wash buffer (0.1% TBS-T) and 
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blocked in wash buffer for 1h at room temperature. Equilibration of plates were 
performed by 5x washes with TC buffer (1mM Tris pH 7.5, 1mM CaCl2, MgCl2, 
MnCl2 and 0.1% Tween). Biotinylated LCA (Vector Labs) was diluted to 1µg/mL in 
TC buffer and added to plates for 1h at 37°C. Streptavidin-HRP was diluted in 0.1% 
TBS-T and incubated for 20min at room temperature. The reaction was started by 
addition of TMB substrate solution and stopped with 2N sulphuric acid.  
CD64 binding assay; Human recombinant FcγRI/CD64 (Life Technologies) was 
diluted to 1µg/mL in PBS and coated in a half-area microtiter ELISA plates (Corning) 
at 37°C for 2h. Plate was washed 3x with PBS-T (0.05%) between each of the 
following step. Plate was blocked in 1% BSA in PBS for 1h at room temperature. 
Antibodies were diluted in antibody diluent (0.1% BSA, 0.05% Tween-20 in tris-
buffered saline) and added to the plate for 1.5h at room temperature. Rabbit F(ab’)2 
anti-human (DAKO Cytomation, P0406) was diluted 1:800 in antibody diluent and 
incubated for 45min at room temperature. eaction was started by addition of TMB 
and stopped with 2N sulphuric acid.  
THP-1 binding assay; THP-1 cells were incubated with antibodies at different 
concentrations for 1h at room-temperature. Bound antibodies were visualized by 
addition of a rabbit F(ab’)2 anti-human (DAKO Cytomation, F0315) as recommended 
by manufacturer. All cell and antibody dilutions were made in PBS supplemented 
with 2% FBS. Mean fluorescence intensity was determined by a Gallios flow 
cytometer (Beckman-Coulter). Data was analyzed by Kaluza Analysis Software.  
Activation of complement by antibodies specific to HMGB1; Microtiter plates 
(Maxisorp, Nunc) were coated with 5µg/mL of antibodies and controls (human serum 
albumin (HSA) and aggregated human IgG), diluted in PBS for 2h at 37°C. Between 
each incubation step, wells were washed 4x with immunowash (50mM Tris-HCl pH 
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8.0, 150mM NaCl, 0.1% Tween-20). After blocking the wells with 1% BSA in PBS 
for 1h at 37°C, wells were incubated with increasing amounts of normal human serum 
(NHS) diluted in GVB2+ (5mM veronal buffer pH 7.4, 144mM NaCl, 1mM MgCl2, 
0.15mM CaCl2, and 1% gelatin) for 45min at 37°C. Deposited C1q was detected with 
specific antibodies (DAKO, A0136) followed by HRP-conjugated secondary 
antibodies (DAKO, P0399). The plates were developed with o-phenylenediamine 
(OPD) substrate (DAKO) and H2O2 and the absorbance at 490 nm was measured. 
Binding of specific antibodies to HMGB1 and activation of complement; 
Microtiter plates (Maxisorp, Nunc) were coated with 5µg/mL HMGB1 in PBS, 
overnight at 4°C. After blocking the wells with 1% BSA in PBS for 1h at 37°C, wells 
were incubated with 5µg/mL of antibodies and controls diluted in PBS for 1h at room 
temperature. Increasing amounts of NHS diluted in GVB2+ were added and incubated 
for 45min at 37°C. Deposited C1q was then detected as described previously. 
Animal procedures 
The protocols were approved and performed in accordance with outlines in a 
license granted under the Animals (Scientific Procedures) Act 1986 and approved by 
the University of Liverpool Animal Ethics Committee (United Kingdom) or by the 
north ethical committee in Stockholm (Sweden). Eight week old male C57BL/6J or 
CD-1 mice (20-25g) were purchased from Charles River laboratories and had a 7-day 
acclimatization period in a 12h light/dark cycle and food and water was given ad 
libitum prior to experiments.  
Mice (n = 6 or 10 for C57BL/6 or n = 7 for CD-1 mice) were fasted overnight for 
15-16h. SI Figure1. Animals were challenged with an intraperitoneal (IP) injection of 
APAP (530mg/kg or 300mg/kg when indicated) or vehicle (0.9% saline). At 2h post-
APAP (or 6h when indicated), mice were given 300µg of indicated antibody (or as 
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stated), 500mg/kg NAC or an equal volume PBS. At 10h post-APAP (or 24h when 
indicated), mice were sacrificed using CO2 and blood was taken by cardiac puncture. 
Serum was isolated by centrifugation at 1500g for 10min at 4°C. Livers were snap 
frozen in liquid nitrogen and stored at -80°C, or fixed in 4% PFA overnight at 4°C. 
Histological determination of hepatotoxicity 
Fixed liver sections were embedded in paraffin wax and 3µm sections were prepared 
and stained with hematoxylin and eosin (H&E) or Periodic Acid Schiff (PAS) stain. 
All sections were examined and the degree of hepatotoxicity was scored according 
previously used criteria [3]. All examination and scoring of sections was performed 
by Prof. A. Kipar, in a blinded manner.  
Immuno-histochemistry stainings 
Liver sections were deparaffinized in xylene and rehydrated with ethanol. 
Subsequently, for antigen retrieval the slides were thermally processed in citrate 
buffer (pH 6.0) using Retriever2100 (Electron Microscopy Sciences, Hatfield, PA, 
USA) prior to immunostaining. To block endogenous peroxidase activity, sections 
were treated with 1% H2O2 followed by a blocking buffer provided by the Histostain 
kit (Life Technologies) followed by an avidin, biotin blocking step (Vector 
Laboratories Inc., Burlingame, USA). The slides were thereafter incubated over night 
with a rabbit anti-HMGB1 antibody (5µg/ml, ab18256, Abcam, Cambridge, MA, 
USA) or rabbit anti-Ki67 antibody (abcam ab16667, diluted 1/100). For HMGB1, 
immunochemical reactions were developed using the Histostain Plus 3-amino-9-
ethylcarbazol (AEC) detection system (Life Technologies) and Ki67 was visualized 
using Bright Vision Ultimate DAB system (Immunologic, Duiven, Netherlands) 
before counterstained with hematoxylin. In each assay, a primary rabbit 
immunoglobulin of irrelevant antigen-specificity was included as a negative control 
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(Negative rabbit control, DAKO). Assessment of proliferation in the liver was 
performed by counting the number of Ki67 positive cells per mm2 using Leica QWin 
V3 tips cell count image analysis program. In total, 7 fields per liver section were 
analyzed in 6 individual mice for m2G7, h2G7 and PBS. For E2 n=5. 
Determination of total hepatic glutathione (GSH) 
Total hepatic GSH was determined as described previously [4]. Briefly, 30-50mg 
of liver was homogenized in 800µL of GSH stock buffer (143mM NaH2PO4, 6.3mM 
EDTA, pH 7.4) supplemented with 200µL of 6.5% (w/v) SSA and incubated on ice 
for 10min in order to deproteinize samples. Homogenates were centrifuged (18400g, 
5min, 4°C) and the supernatants stored at -80°C. The protein pellets were dissolved in 
1M NaOH at 60°C for 1h and protein concentration of the dissolved pellet was 
determined using Bio-Rad protein assay (Bio-Rad Laboratories, Hemel Hempstead, 
UK). GSH content of the supernatants was measured by kinetic reaction (at 412nm) 
as previously described [5]. GSH in samples was compared to a 0 – 40 nmoles/mL 
standard curve and all samples were normalized to protein content. 
Determination of alanine aminotransferase (ALT) activity in serum 
Serum ALT activity was determined by kinetic assay according to the 
manufacturer’s instructions (Thermo Scientific). 30µL of serum was loaded in 
duplicate into 96-well plates. ALT reagent was heated to 37°C and 300µL per well 
was added to samples and assayed at 340nm.  
MicroRNA 122 (miR-122) quantification in serum 
miR-122 was quantified in serum as previously described [6]. Total miRNA was 
extracted and purified using a miRNeasy kit followed by an RNeasy MinElute 
Cleanup Kit (Qiagen, Venlo, Netherlands), in accordance with the manufacturer’s 
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instructions. The RNA was eluted in 14µL of nuclease-free water before storing at -
80°C until further use. 
Reverse transcription was performed using a TaqMan miRNA reverse 
transcription kit (Applied Biosystems) and miR-122 and Let-7d (endogenous miRNA 
control) primers. Briefly, 2µL purified miRNA was used to synthesise cDNA with a 
total reaction volume of 15µL via thermal cycling (30min at 16°C, 30min at 42°C, 
5min at 85°C and then held at 4°C). Quantitative-PCR (qPCR) reactions were run in 
duplicate in 384-well plates using TaqMan PCR Primers and Master Mix (Applied 
Biosystems) according to manufacturer’s instructions. 1.33µL of cDNA was used and 
the total reaction volume was made up to 20µL with primer/master mix, and subject 
to thermal cycling (2min at 50°C, 10min at 95°C and 50 cycles of 15sec at 95°C and 
60sec at 60°C). miR-122 levels were subsequently normalized to the level of let-7d. 
Chemo- and cytokine quantification in serum 
Serum MCP-1, CXCL-1, TNF, IFNγ, IL-1β and IL-6 concentration was 
determined by cytokine bead array (CBA) according to the manufacturer’s 
instructions (BD Biosciences).  
Statistical analysis 
For in vivo studies, Kruskal-Wallis with Dunns post-test was performed. For in 
vitro data, two-tailed t-test was performed where indicated. All statistical analysis was 
performed using Graphpad Prism.  
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Supplementary Table 1.  
Beneficial effects of m2G7 treatment in diverse experimental models 
Year Author Effects of m2G7 treatment Associated disease  
2005 Tsung A, et al. [7] Reduced liver injury and inflammation 
Ischemia / 
Reperfusion injury 
S
te
r
il
e
 i
n
fl
a
m
m
a
ti
o
n
 
2010 Gao Q, et al. [8] 
Reduced inflammation and improved 
pancreatic islet viability 
Organ transplantation 
2011 Schierbeck H, et al. [9] Reduced clinical signs of arthritis Arthritis 
2014 Agalave NM, et al. [10] Reduced pain hypersensitivity Arthritis 
2014 Parker KH, et al. [11] 
Reduced number of myeloid-derived 
suppressor cells in tumors 
Cancer 
2015 Yang H, et al. [12] 
Improved survival, reduced liver injury 
and inflammation 
Acetaminophen-induced 
liver injury 
   
 
  
2006 Qin S, et al. [13] Improved survival Sepsis 
In
fe
ct
io
u
s 
2012 Entezari M, et al. [14] 
Prot cted against neutrophil recruitment, 
lung injury and bacterial infection 
Pulmonary infection with 
P.aeruginosa 
2012 Chavan SS, et al. [15] Reduced cognitive impairment Sepsis 
2013 Achouiti A, et al. [16] 
Reduced lung pathology and 
inflammation 
Pneumonia 
2013 Patel VS, et al. [17] 
Reduced bacterial counts and lung 
injury 
Respiratory distress/ 
hypoxia 
2013 Valdés-Ferrer SI, et al. [18] 
Reduced splenomegaly and 
inflammation 
Sepsis 
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Supplementary Table 2.  
Cloning primes 
use  sequence (5’ – 3’) restriction site 
IgGγ 
forward CTGCAACCGGTGTACATTCCCAGGTGCAGCTGCAGCAGTCTGG AgeI 
reverse TGCGAAGTCGACGCTGCAGAGACAGTGACCAGAG SalI 
IgGκ 
forward CTGCAACCGGTGTACATTCCGAAAATGTTCTCACCCAGTCTCCA AgeI 
reverse GCCACCGTACGTTTTATTTCCAGCTTGGTC BsiWI 
HMGB1-HIS 
forward GCGCCATGGGCAAAGGAGATCCTAAGA NcoI 
reverse GCGCTCGAGTTCATCATCATCATCTTCT XhoI 
box A-HIS 
forward GCGCCATGGGCAAAGGAGATCCTAAGA NcoI 
reverse GCGCTCGAGGAACTTCTTTTTTGTCTCC XhoI 
box B-HIS 
forward AAGCCATGGGCAAGGATCCCAATGCAC NcoI 
reverse GCGCTCGAGGACAACTCCCTTTTTTGCT XhoI 
K322A 
forward CAAGGAGTACAAGTGCGCGGTCTCCAACAAAGC  
reverse GCTTTGTTGGAGACCGCGCACTTGTACTCCTTG  
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Supplementary Fig. 1 
Schematic in vivo experimental overview. Mice were fasted for 15-16h before 
challenge IP with APAP (530mg/kg). At 2h post-APAP mice were treated with either 
PBS (vehicle) or 300µg of indicated antibodies. Mice were euthanized at 10h post-
APAP. Serum ALT and miR-122 were measured as markers of hepatotoxicity and 
serum TNF, CXCL-1 and MCP-1 were used as markers of inflammation. Livers were 
harvested for histological analysis and to determine hepatic glutathione (GSH).  
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Supplementary Fig. 2. 
Antibody treatments alone do not affect the baseline levels of hepatic injury in non-
APAP challenged mice. (A) Serum ALT or (B) serum miR-122 in non-APAP 
challenged C57BL/6 mice. Results are represented as means±SEM. 
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Supplementary Fig. 3. 
Representative liver from normal C57BL/6 mice stained with hematoxylin and eosin 
(H&E, upper left) or for HMGB1 expression (upper right). C57BL/6 mice exposed 
with APAP (530mg/kg) for 10h were stained were stained with either H&E (lower 
left) or for HMGB1 expression (lower right).  
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Supplementary Fig. 4. 
2G7 treatment reduces hepatocyte proliferation in APAP-challenged mice. C57BL/6 
mice were challenged with APAP (530mg/kg) for 10h. At 2h post-APAP, mice were 
treated with either PBS (vehicle) or 300µg of indicated antibodies. The effect on 
hepatocyte proliferation was evaluated by Ki67 staining (n=6 for PBS, m2G7 and 
h2G7 and n=5 for E2 treated mice).  
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Supplementary Fig. 5. 
2G7 or box A does not affect APAP metabolism or liver injury markers in non-APAP 
exposed CD-1 mice. (A) Effect on hepatic glutathione (GSH) and GSH depletion 
following APAP exposure. (B) Treatments did not affect serum ALT in non-APAP 
challenged CD-1 mice. Results are represented as means±SEM 
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Supplementary Fig. 6. 
Effects of endoS treatment of h2G7. EndoS treatment of h2G7 dose-dependently 
affects its binding to (A) LCA, (B) human CD64 and (C) live THP-1 cells.  
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Supplementary Fig. 7. 
Effector function deficient h2G7 variants do not affect liver injury in APAP exposed 
mice. (A) Effect on serum miR-122 expression in C57BL/6 mice. Results are 
represented as means±SEM. 
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